- Home
- NVNI vs NRXP Comparison
NVNI vs NRXP Comparison
Compare NVNI & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNI
- NRXP
- Stock Information
- Founded
- NVNI 2019
- NRXP 2015
- Country
- NVNI Brazil
- NRXP United States
- Employees
- NVNI N/A
- NRXP N/A
- Industry
- NVNI
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- NVNI
- NRXP Health Care
- Exchange
- NVNI Nasdaq
- NRXP Nasdaq
- Market Cap
- NVNI 31.5M
- NRXP 32.6M
- IPO Year
- NVNI N/A
- NRXP N/A
- Fundamental
- Price
- NVNI $0.35
- NRXP $3.27
- Analyst Decision
- NVNI
- NRXP Strong Buy
- Analyst Count
- NVNI 0
- NRXP 4
- Target Price
- NVNI N/A
- NRXP $28.50
- AVG Volume (30 Days)
- NVNI 1.3M
- NRXP 215.7K
- Earning Date
- NVNI 08-07-2025
- NRXP 08-13-2025
- Dividend Yield
- NVNI N/A
- NRXP N/A
- EPS Growth
- NVNI N/A
- NRXP N/A
- EPS
- NVNI N/A
- NRXP N/A
- Revenue
- NVNI $31,250,627.00
- NRXP N/A
- Revenue This Year
- NVNI $12.05
- NRXP N/A
- Revenue Next Year
- NVNI $15.02
- NRXP N/A
- P/E Ratio
- NVNI N/A
- NRXP N/A
- Revenue Growth
- NVNI 1491.58
- NRXP N/A
- 52 Week Low
- NVNI $0.14
- NRXP $1.10
- 52 Week High
- NVNI $12.19
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- NVNI 52.81
- NRXP 53.62
- Support Level
- NVNI $0.28
- NRXP $2.90
- Resistance Level
- NVNI $0.38
- NRXP $3.53
- Average True Range (ATR)
- NVNI 0.03
- NRXP 0.20
- MACD
- NVNI 0.01
- NRXP -0.04
- Stochastic Oscillator
- NVNI 71.58
- NRXP 58.73
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.